AZN Gets EU Nod for Expanded Use of Two Separate Cancer Drugs

AstraZeneca (AZN) and partner Daiichi Sankyo announced that the European Commission has approved the expanded use of Enhertu (trastuzumab deruxtecan) in breast cancer.The regulatory body has now approved Enhertu as a monotherapy for treating metastatic HR-positive, HER2-low or HER2-ultralow breast cancer in adult patients who have received at least one endocrine therapy in the metastatic setting and are not considered suitable for the therapy as the next line of treatment in the European Union (“EU”).The la ...